Effects of Fructose Restriction on Liver Steatosis
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Feb 24, 2017
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Body mass index ≥ 28 kg/m2
- • Fatty liver index ≥ 60
- • Fructose intake ≥45 grams/day
- Exclusion Criteria:
- • Medical history of liver disease
- • (History of) excessive alcohol consumption (defined as \> 2 units/day for women, and \> 3 units/day for men)
- • Major change in weight and/or physical activity prior to the study
- • Use of glucose lowering drugs
- • Recent illness
- • Pregnancy and/or lactation
- • Contraindications for magnetic resonance imaging
- • Inability to give informed consent
- • Protocol change (implemented on July 18, 2018): in order to increase the inclusion of study participants, subjects with an average daily fructose intake \< 45 gram/day will also be eligible for participation. In subjects who have an average daily fructose intake \< 45 gram/day, supplementation of either fructose or glucose (see 'Arms and Interventions') will be increased to 45 gram/day.
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, Limburg, Netherlands
Patients applied
Trial Officials
Martijn CG Brouwers, MD,PhD
Principal Investigator
Maastricht University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials